Novem Group Acquires New Holdings in Insulet Corporation $PODD

Key Points

• Novem Group has acquired a new stake in Insulet Corporation, purchasing 3,325 shares valued at approximately $1,045,000 during the second quarter.
• Insulet's recent quarterly earnings report showed earnings per share of $1.17, exceeding the consensus estimate of $0.92, with a revenue increase of 32.9% year-over-year.
• Several large investors, including Toronto Dominion Bank and Mackenzie Financial Corp, have significantly increased their stakes in Insulet during the fourth quarter.

Novem Group acquired a new stake in Insulet Corporation (NASDAQ:PODD - Free Report) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 3,325 shares of the medical instruments supplier's stock, valued at approximately $1,045,000.

A number of other large investors have also recently added to or reduced their stakes in PODD. Toronto Dominion Bank grew its stake in Insulet by 55.2% in the 4th quarter. Toronto Dominion Bank now owns 36,486 shares of the medical instruments supplier's stock valued at $9,526,000 after acquiring an additional 12,984 shares during the last quarter. Mackenzie Financial Corp grew its stake in Insulet by 7.0% in the 4th quarter. Mackenzie Financial Corp now owns 7,561 shares of the medical instruments supplier's stock valued at $1,974,000 after acquiring an additional 493 shares during the last quarter. Universal Beteiligungs und Servicegesellschaft mbH acquired a new stake in Insulet in the 4th quarter valued at about $29,993,000. Siemens Fonds Invest GmbH acquired a new stake in Insulet in the 4th quarter valued at about $201,000. Finally, Wealth Enhancement Advisory Services LLC grew its stake in Insulet by 16.9% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 2,658 shares of the medical instruments supplier's stock valued at $694,000 after acquiring an additional 384 shares during the last quarter.

Insider Activity at Insulet

In related news, SVP Laetitia Cousin sold 797 shares of the firm's stock in a transaction that occurred on Monday, September 8th. The shares were sold at an average price of $348.81, for a total value of $278,001.57. Following the transaction, the senior vice president owned 3,890 shares in the company, valued at approximately $1,356,870.90. This trade represents a 17.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, SVP Prem Singh sold 687 shares of the firm's stock in a transaction that occurred on Monday, September 8th. The shares were sold at an average price of $347.49, for a total transaction of $238,725.63. Following the completion of the transaction, the senior vice president owned 3,456 shares in the company, valued at $1,200,925.44. The trade was a 16.58% decrease in their position. The disclosure for this sale can be found here. Company insiders own 0.39% of the company's stock.

Insulet Trading Down 1.0%

Shares of PODD stock opened at $323.58 on Friday. The firm has a market cap of $22.78 billion, a P/E ratio of 98.35, a PEG ratio of 2.71 and a beta of 1.36. Insulet Corporation has a 1-year low of $225.37 and a 1-year high of $353.50. The company has a debt-to-equity ratio of 0.64, a current ratio of 2.26 and a quick ratio of 1.81. The firm's 50-day simple moving average is $318.33 and its 200-day simple moving average is $296.13.

Insulet (NASDAQ:PODD - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $1.17 earnings per share for the quarter, topping the consensus estimate of $0.92 by $0.25. The business had revenue of $649.10 million for the quarter, compared to analyst estimates of $612.31 million. Insulet had a net margin of 10.01% and a return on equity of 23.78%. The company's revenue was up 32.9% on a year-over-year basis. During the same period in the prior year, the firm posted $0.55 EPS. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. As a group, equities analysts forecast that Insulet Corporation will post 3.92 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on PODD shares. Citigroup reissued a "buy" rating on shares of Insulet in a research note on Tuesday, July 8th. Canaccord Genuity Group upped their target price on shares of Insulet from $331.00 to $353.00 and gave the company a "buy" rating in a report on Friday, August 8th. Wall Street Zen upgraded shares of Insulet from a "hold" rating to a "buy" rating in a report on Saturday, August 9th. Jefferies Financial Group restated a "buy" rating on shares of Insulet in a report on Thursday, August 7th. Finally, JPMorgan Chase & Co. upped their target price on shares of Insulet from $340.00 to $415.00 and gave the company an "overweight" rating in a report on Friday, September 12th. Sixteen investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $343.06.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.

Want to see what other hedge funds are holding PODD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insulet Corporation (NASDAQ:PODD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.